Přehled o publikaci
2024
Clinical efficacy and safety of first-line nilotinib or imatinib therapy in patients with chronic myeloid leukemia-Nationwide real life data
BELOHLAVKOVA, Petra; Daniela ŽÁČKOVÁ; Hana KLAMOVA; Edgar FABER; Michal KARAS et al.Basic information
Original name
Clinical efficacy and safety of first-line nilotinib or imatinib therapy in patients with chronic myeloid leukemia-Nationwide real life data
Authors
BELOHLAVKOVA, Petra; Daniela ŽÁČKOVÁ; Hana KLAMOVA; Edgar FABER; Michal KARAS; Lukas STEJSKAL; Eduard CMUNT; Olga CERNA; Ivana JEŽÍŠKOVÁ; Katerina MACHOVA POLAKOVA; Pavel ZAK; Tereza JURKOVÁ; Marika CHRÁPAVÁ and Jiří MAYER
Edition
Cancer Medicine, Hoboken, Sons Ltd. 2024, 2045-7634
Other information
Language
English
Type of outcome
Article in a journal
Country of publisher
United States of America
Confidentiality degree
is not subject to a state or trade secret
References:
Marked to be transferred to RIV
Yes
RIV identification code
RIV/00216224:14110/24:00137202
Organization
Lékařská fakulta – Repository – Repository
UT WoS
EID Scopus
Keywords in English
chronic myeloid leukemia; first-line treatment; imatinib; nilotinib
Links
LX22NPO5102, research and development project.
Changed: 10/6/2025 00:50, RNDr. Daniel Jakubík
Abstract
In the original language
Background: To evaluate the outcomes of first- line imatinib versus nilotinib treatment for chronic myeloid leukemia in the chronic phase (CML- CP) in real-world clinical practice. Methods: A propensity score analysis was performed to eliminate imbalances between the treatment groups. In the analysis, 163 patients in the nilotinib group and 163 patients in the matched imatinib group were retrospectively evaluated. Results: Nilotinib- treated patients achieved complete cytogenetic response (CCyR) and major molecular response more rapidly than imatinib-treated patients. However, there was no significant difference in 5- year overall survival (OS) or progression- free survival (PFS) between the two groups (OS: 94.3% vs. 90.5%, p = 0.602; PFS: 92.9% vs. 88.0%, p = 0.614). Nilotinib- treated patients had a higher failure- free survival (FFS) and event- free survival (EFS) than imatinib-treated patients (FFS: 71.7% vs. 54.3%, p = 0.040; EFS: 71.7% vs. 53.5%, p = 0.025). Conclusions: This retrospective analysis from clinical practice did not confirm any benefit of frontline nilotinib treatment for OS and PFS; however, it did demonstrate higher FFS and EFS in the nilotinib cohort.
